Effect of fecal microbiota transplantation on recurrence in multiply recurrent clostridium difficile infection a randomized trial

Colleen R. Kelly, Alexander Khoruts, Christopher Staley, Michael J. Sadowsky, Mortadha Abd, Mustafa Alani, Brianna Bakow, Patrizia Curran, Joyce McKenney, Allison Tisch, Steven E. Reinert, Jason T. MacHan, Lawrence J. Brandt

Research output: Contribution to journalArticle

182 Citations (Scopus)

Abstract

Background: To date, evidence for the efficacy of fecal microbiota transplantation (FMT) in recurrent Clostridium difficile infection (CDI) has been limited to case series and open-label clinical trials. Objective: To determine the efficacy and safety of FMT for treatment of recurrent CDI. Design: Randomized, controlled, double-blind clinical trial. (ClinicalTrials.gov: NCT01703494) Setting: Two academic medical centers. Patients: 46 patients who had 3 or more recurrences of CDI and received a full course of vancomycin for their most recent acute episode. Intervention: Fecal microbiota transplantation with donor stool (heterologous) or patient's own stool (autologous) administered by colonoscopy. Measurements: The primary end point was resolution of diarrhea without the need for further anti-CDI therapy during the 8-week follow-up. Safety data were compared between treatment groups via review of adverse events (AEs), serious AEs (SAEs), and new medical conditions for 6 months after FMT. Fecal microbiota analyses were performed on patients' stool before and after FMT and also on donors' stool. Results: In the intention-to-treat analysis, 20 of 22 patients (90.9%) in the donor FMT group achieved clinical cure compared with 15 of 24 (62.5%) in the autologous FMT group (P = 0.042). Resolution after autologous FMT differed by site (9 of 10 vs. 6 of 14 [P = 0.033]). All 9 patients who developed recurrent CDI after autologous FMT were free of further CDI after subsequent donor FMT. There were no SAEs related to FMT. Donor FMT restored gut bacterial community diversity and composition to resemble that of healthy donors. Limitation: The study included only patients who had 3 or more recurrences and excluded those who were immunocompromised and aged 75 years or older. Conclusion: Donor stool administered via colonoscopy seemed safe and was more efficacious than autologous FMT in preventing further CDI episodes. Primary Funding Source: National Institute of Diabetes and Digestive and Kidney Diseases.

Original languageEnglish (US)
Pages (from-to)609-616
Number of pages8
JournalAnnals of Internal Medicine
Volume165
Issue number9
DOIs
StatePublished - Nov 1 2016

Fingerprint

Clostridium Infections
Clostridium difficile
Recurrence
Tissue Donors
Colonoscopy
Fecal Microbiota Transplantation
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.)
Clinical Trials
Safety
Intention to Treat Analysis
Microbiota
Vancomycin

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Effect of fecal microbiota transplantation on recurrence in multiply recurrent clostridium difficile infection a randomized trial. / Kelly, Colleen R.; Khoruts, Alexander; Staley, Christopher; Sadowsky, Michael J.; Abd, Mortadha; Alani, Mustafa; Bakow, Brianna; Curran, Patrizia; McKenney, Joyce; Tisch, Allison; Reinert, Steven E.; MacHan, Jason T.; Brandt, Lawrence J.

In: Annals of Internal Medicine, Vol. 165, No. 9, 01.11.2016, p. 609-616.

Research output: Contribution to journalArticle

Kelly, CR, Khoruts, A, Staley, C, Sadowsky, MJ, Abd, M, Alani, M, Bakow, B, Curran, P, McKenney, J, Tisch, A, Reinert, SE, MacHan, JT & Brandt, LJ 2016, 'Effect of fecal microbiota transplantation on recurrence in multiply recurrent clostridium difficile infection a randomized trial', Annals of Internal Medicine, vol. 165, no. 9, pp. 609-616. https://doi.org/10.7326/M16-0271
Kelly, Colleen R. ; Khoruts, Alexander ; Staley, Christopher ; Sadowsky, Michael J. ; Abd, Mortadha ; Alani, Mustafa ; Bakow, Brianna ; Curran, Patrizia ; McKenney, Joyce ; Tisch, Allison ; Reinert, Steven E. ; MacHan, Jason T. ; Brandt, Lawrence J. / Effect of fecal microbiota transplantation on recurrence in multiply recurrent clostridium difficile infection a randomized trial. In: Annals of Internal Medicine. 2016 ; Vol. 165, No. 9. pp. 609-616.
@article{4b6ed0274e254606b5ceda13fce14b03,
title = "Effect of fecal microbiota transplantation on recurrence in multiply recurrent clostridium difficile infection a randomized trial",
abstract = "Background: To date, evidence for the efficacy of fecal microbiota transplantation (FMT) in recurrent Clostridium difficile infection (CDI) has been limited to case series and open-label clinical trials. Objective: To determine the efficacy and safety of FMT for treatment of recurrent CDI. Design: Randomized, controlled, double-blind clinical trial. (ClinicalTrials.gov: NCT01703494) Setting: Two academic medical centers. Patients: 46 patients who had 3 or more recurrences of CDI and received a full course of vancomycin for their most recent acute episode. Intervention: Fecal microbiota transplantation with donor stool (heterologous) or patient's own stool (autologous) administered by colonoscopy. Measurements: The primary end point was resolution of diarrhea without the need for further anti-CDI therapy during the 8-week follow-up. Safety data were compared between treatment groups via review of adverse events (AEs), serious AEs (SAEs), and new medical conditions for 6 months after FMT. Fecal microbiota analyses were performed on patients' stool before and after FMT and also on donors' stool. Results: In the intention-to-treat analysis, 20 of 22 patients (90.9{\%}) in the donor FMT group achieved clinical cure compared with 15 of 24 (62.5{\%}) in the autologous FMT group (P = 0.042). Resolution after autologous FMT differed by site (9 of 10 vs. 6 of 14 [P = 0.033]). All 9 patients who developed recurrent CDI after autologous FMT were free of further CDI after subsequent donor FMT. There were no SAEs related to FMT. Donor FMT restored gut bacterial community diversity and composition to resemble that of healthy donors. Limitation: The study included only patients who had 3 or more recurrences and excluded those who were immunocompromised and aged 75 years or older. Conclusion: Donor stool administered via colonoscopy seemed safe and was more efficacious than autologous FMT in preventing further CDI episodes. Primary Funding Source: National Institute of Diabetes and Digestive and Kidney Diseases.",
author = "Kelly, {Colleen R.} and Alexander Khoruts and Christopher Staley and Sadowsky, {Michael J.} and Mortadha Abd and Mustafa Alani and Brianna Bakow and Patrizia Curran and Joyce McKenney and Allison Tisch and Reinert, {Steven E.} and MacHan, {Jason T.} and Brandt, {Lawrence J.}",
year = "2016",
month = "11",
day = "1",
doi = "10.7326/M16-0271",
language = "English (US)",
volume = "165",
pages = "609--616",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "9",

}

TY - JOUR

T1 - Effect of fecal microbiota transplantation on recurrence in multiply recurrent clostridium difficile infection a randomized trial

AU - Kelly, Colleen R.

AU - Khoruts, Alexander

AU - Staley, Christopher

AU - Sadowsky, Michael J.

AU - Abd, Mortadha

AU - Alani, Mustafa

AU - Bakow, Brianna

AU - Curran, Patrizia

AU - McKenney, Joyce

AU - Tisch, Allison

AU - Reinert, Steven E.

AU - MacHan, Jason T.

AU - Brandt, Lawrence J.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background: To date, evidence for the efficacy of fecal microbiota transplantation (FMT) in recurrent Clostridium difficile infection (CDI) has been limited to case series and open-label clinical trials. Objective: To determine the efficacy and safety of FMT for treatment of recurrent CDI. Design: Randomized, controlled, double-blind clinical trial. (ClinicalTrials.gov: NCT01703494) Setting: Two academic medical centers. Patients: 46 patients who had 3 or more recurrences of CDI and received a full course of vancomycin for their most recent acute episode. Intervention: Fecal microbiota transplantation with donor stool (heterologous) or patient's own stool (autologous) administered by colonoscopy. Measurements: The primary end point was resolution of diarrhea without the need for further anti-CDI therapy during the 8-week follow-up. Safety data were compared between treatment groups via review of adverse events (AEs), serious AEs (SAEs), and new medical conditions for 6 months after FMT. Fecal microbiota analyses were performed on patients' stool before and after FMT and also on donors' stool. Results: In the intention-to-treat analysis, 20 of 22 patients (90.9%) in the donor FMT group achieved clinical cure compared with 15 of 24 (62.5%) in the autologous FMT group (P = 0.042). Resolution after autologous FMT differed by site (9 of 10 vs. 6 of 14 [P = 0.033]). All 9 patients who developed recurrent CDI after autologous FMT were free of further CDI after subsequent donor FMT. There were no SAEs related to FMT. Donor FMT restored gut bacterial community diversity and composition to resemble that of healthy donors. Limitation: The study included only patients who had 3 or more recurrences and excluded those who were immunocompromised and aged 75 years or older. Conclusion: Donor stool administered via colonoscopy seemed safe and was more efficacious than autologous FMT in preventing further CDI episodes. Primary Funding Source: National Institute of Diabetes and Digestive and Kidney Diseases.

AB - Background: To date, evidence for the efficacy of fecal microbiota transplantation (FMT) in recurrent Clostridium difficile infection (CDI) has been limited to case series and open-label clinical trials. Objective: To determine the efficacy and safety of FMT for treatment of recurrent CDI. Design: Randomized, controlled, double-blind clinical trial. (ClinicalTrials.gov: NCT01703494) Setting: Two academic medical centers. Patients: 46 patients who had 3 or more recurrences of CDI and received a full course of vancomycin for their most recent acute episode. Intervention: Fecal microbiota transplantation with donor stool (heterologous) or patient's own stool (autologous) administered by colonoscopy. Measurements: The primary end point was resolution of diarrhea without the need for further anti-CDI therapy during the 8-week follow-up. Safety data were compared between treatment groups via review of adverse events (AEs), serious AEs (SAEs), and new medical conditions for 6 months after FMT. Fecal microbiota analyses were performed on patients' stool before and after FMT and also on donors' stool. Results: In the intention-to-treat analysis, 20 of 22 patients (90.9%) in the donor FMT group achieved clinical cure compared with 15 of 24 (62.5%) in the autologous FMT group (P = 0.042). Resolution after autologous FMT differed by site (9 of 10 vs. 6 of 14 [P = 0.033]). All 9 patients who developed recurrent CDI after autologous FMT were free of further CDI after subsequent donor FMT. There were no SAEs related to FMT. Donor FMT restored gut bacterial community diversity and composition to resemble that of healthy donors. Limitation: The study included only patients who had 3 or more recurrences and excluded those who were immunocompromised and aged 75 years or older. Conclusion: Donor stool administered via colonoscopy seemed safe and was more efficacious than autologous FMT in preventing further CDI episodes. Primary Funding Source: National Institute of Diabetes and Digestive and Kidney Diseases.

UR - http://www.scopus.com/inward/record.url?scp=84994469092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994469092&partnerID=8YFLogxK

U2 - 10.7326/M16-0271

DO - 10.7326/M16-0271

M3 - Article

C2 - 27547925

AN - SCOPUS:84994469092

VL - 165

SP - 609

EP - 616

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 9

ER -